Improvement after aflibercept in vitrectomized eyes with DME maintained for 2 years
Improvements of visual and anatomical outcomes after intravitreal aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) were maintained for 2 years, according to a study.
In this prospective, non-comparative, multicenter observational study, 28 eyes with DME previously vitrectomized treated with IAI during ≥2 years. Treatment included 5 monthly IAI followed by a ProReNata regimen during the first year. During the second year, clinicians’ discretion was used to switch eyes to a Treat and Extend or Observe and Plan regimen.
At 2 years, the visual gain was +5.4 letters and central macular thickness decreased significantly (-62µm, P < 0.001). In 15% of eyes (n = 7), aflibercept was discontinued after resolution of macular edema.
The mean number of injections was 14.6 and mean interval injection was 6.4 weeks for 2 years.
Tran THC, Verdun S, Le Rouic JF, et al. Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema. Clin Ophthalmol. 2022;16:603-609. doi: 10.2147/OPTH.S352152. PMID: 35310546; PMCID: PMC8923833.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809